49 results
424B5
VKTX
Viking Therapeutics Inc
1 Mar 24
Prospectus supplement for primary offering
4:13pm
of domestic law by virtue of the European Union (Withdrawal) Act 2018.
In addition, in the United Kingdom, this prospectus supplement is being
8-K
EX-1.1
VKTX
Viking Therapeutics Inc
1 Mar 24
Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock
4:05pm
. Department of Treasury’s Office of Foreign Assets Control, the United Nations Security Council, the European Union, His Majesty’s Treasury or other relevant
424B5
VKTX
Viking Therapeutics Inc
27 Feb 24
Prospectus supplement for primary offering
5:21pm
and the expression “U.K. Prospectus Regulation” means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act
S-3ASR
EX-4.2
y078w p401weiows
26 Jul 23
Automatic shelf registration
5:26pm
8-K
EX-1.1
m34zt4du7vx n0
31 Mar 23
Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock
5:27pm
424B5
skckh0vgaj28y24pyarm
31 Mar 23
Prospectus supplement for primary offering
5:24pm
424B5
60mthfg08rr ljih8sfg
29 Mar 23
Prospectus supplement for primary offering
4:01pm